Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Sep 3;43(22):10689–10699. doi: 10.1093/nar/gkv867

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Expression level changes of imprinted genes in human cancers. (A) Expression levels of imprinted genes (represented by columns) were compared between the primary tumor and normal solid tissue cells of various cancers (represented by rows) using TCGA database (The Cancer Genome Atlas). Statistically significant down- and upregulations were indicated by green and red boxes, respectively, while no significant change with gray boxes. XIST has been included in this series of analyses due to its 50% DNA methylation levels in females although it is not an imprinted gene. The actual table used for this image is available as Supplementary Data 1. (B) This graph summarizes how many imprinted genes show down and upregulations for each cancer type. (C) This graph summarizes in how many cancer types the expression levels of each imprinted gene are changed between the tumor and normal cells. Individual cancer types are represented with the following abbreviations: BRCA (breast invasive carcinoma), KICH (kidney chromophobe), LUAD (lung adenocarcinoma), LUNG (lung cancer), KIRC (kidney renal clear cell carcinoma), UCEC (uterine corpus endometrioid carcinoma), COADREAD (colon and rectum adenocarcinoma), COAD (colon adenocarcinoma), PRAD (prostate adenocarcinoma), LUSC (lung squamous cell carcinoma), THCA (thyroid carcinoma), KIRP (kidney renal papillary cell carcinoma), GBM (glioblastoma multiforme), STAD (stomach adenocarcinoma), BLCA (bladder urothelial carcinoma), READ (rectum adenocarcinoma), LAML (acute myeloid leukemia), LIHC (liver hepatocellular carcinoma), ESCA (esophageal carcinoma), CESC (cervical squamous cell carcinoma and endocervical adenocarcinoma), PCPG (pheochromocytoma and paraganglioma), SARC (sarcoma) and PAAD (pancreatic adenocarcinoma).